185 related articles for article (PubMed ID: 23250858)
21. Dysplastic definitive hematopoiesis in AML1/EVI1 knock-in embryos.
Maki K; Yamagata T; Asai T; Yamazaki I; Oda H; Hirai H; Mitani K
Blood; 2005 Sep; 106(6):2147-55. PubMed ID: 15914564
[TBL] [Abstract][Full Text] [Related]
22. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.
Sood R; Talwar-Trikha A; Chakrabarti SR; Nucifora G
Leukemia; 1999 Mar; 13(3):348-57. PubMed ID: 10086725
[TBL] [Abstract][Full Text] [Related]
23. The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.
Steinmetz B; Hackl H; Slabáková E; Schwarzinger I; Smějová M; Spittler A; Arbesu I; Shehata M; Souček K; Wieser R
Cell Cycle; 2014; 13(18):2931-43. PubMed ID: 25486480
[TBL] [Abstract][Full Text] [Related]
24. Dysregulated EVI1 expression in myeloid malignancies.
Pardanani A
Leuk Lymphoma; 2006 Dec; 47(12):2443-4. PubMed ID: 17169788
[No Abstract] [Full Text] [Related]
25. Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis.
Senyuk V; Zhang Y; Liu Y; Ming M; Premanand K; Zhou L; Chen P; Chen J; Rowley JD; Nucifora G; Qian Z
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):5594-9. PubMed ID: 23509296
[TBL] [Abstract][Full Text] [Related]
26. Targeting a DNA binding motif of the EVI1 protein by a pyrrole-imidazole polyamide.
Zhang Y; Sicot G; Cui X; Vogel M; Wuertzer CA; Lezon-Geyda K; Wheeler J; Harki DA; Muzikar KA; Stolper DA; Dervan PB; Perkins AS
Biochemistry; 2011 Dec; 50(48):10431-41. PubMed ID: 22039883
[TBL] [Abstract][Full Text] [Related]
27. EVI1 abrogates interferon-alpha response by selectively blocking PML induction.
Buonamici S; Li D; Mikhail FM; Sassano A; Platanias LC; Colamonici O; Anastasi J; Nucifora G
J Biol Chem; 2005 Jan; 280(1):428-36. PubMed ID: 15519999
[TBL] [Abstract][Full Text] [Related]
28. RUNX1-EVI1 disrupts lineage determination and the cell cycle by interfering with RUNX1 and EVI1 driven gene regulatory networks.
Kellaway SG; Keane P; Kennett E; Bonifer C
Haematologica; 2021 Jun; 106(6):1569-1580. PubMed ID: 32299907
[TBL] [Abstract][Full Text] [Related]
29. Comparative expression analysis of the antagonistic transcription factors EVI1 and MDS1-EVI1 in murine tissues and during in vitro hematopoietic differentiation.
Wimmer K; Vinatzer U; Zwirn P; Fonatsch C; Wieser R
Biochem Biophys Res Commun; 1998 Nov; 252(3):691-6. PubMed ID: 9837768
[TBL] [Abstract][Full Text] [Related]
30. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression.
Yuasa H; Oike Y; Iwama A; Nishikata I; Sugiyama D; Perkins A; Mucenski ML; Suda T; Morishita K
EMBO J; 2005 Jun; 24(11):1976-87. PubMed ID: 15889140
[TBL] [Abstract][Full Text] [Related]
31. CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737.
Shimada K; Tomita A; Minami Y; Abe A; Hind CK; Kiyoi H; Cragg MS; Naoe T
Exp Hematol; 2012 Sep; 40(9):724-737.e2. PubMed ID: 22634393
[TBL] [Abstract][Full Text] [Related]
32. The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase.
Vinatzer U; Taplick J; Seiser C; Fonatsch C; Wieser R
Br J Haematol; 2001 Sep; 114(3):566-73. PubMed ID: 11552981
[TBL] [Abstract][Full Text] [Related]
33. Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome.
Dickstein J; Senyuk V; Premanand K; Laricchia-Robbio L; Xu P; Cattaneo F; Fazzina R; Nucifora G
Proc Natl Acad Sci U S A; 2010 May; 107(21):9783-8. PubMed ID: 20448201
[TBL] [Abstract][Full Text] [Related]
34. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
Cuenco GM; Ren R
Oncogene; 2001 Dec; 20(57):8236-48. PubMed ID: 11781838
[TBL] [Abstract][Full Text] [Related]
35. Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemia.
Weisser M; Kern W; Schoch C; Tschulik C; Hiddemann W; Haferlach T; Schnittger S
Leuk Lymphoma; 2006 Dec; 47(12):2645-7. PubMed ID: 17169810
[No Abstract] [Full Text] [Related]
36. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
Katayama S; Suzuki M; Yamaoka A; Keleku-Lukwete N; Katsuoka F; Otsuki A; Kure S; Engel JD; Yamamoto M
Blood; 2017 Aug; 130(7):908-919. PubMed ID: 28630119
[TBL] [Abstract][Full Text] [Related]
37. The shortest isoform of C/EBPβ, liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model.
Watanabe-Okochi N; Yoshimi A; Sato T; Ikeda T; Kumano K; Taoka K; Satoh Y; Shinohara A; Tsuruta T; Masuda A; Yokota H; Yatomi Y; Takahashi K; Kitaura J; Kitamura T; Kurokawa M
Blood; 2013 May; 121(20):4142-55. PubMed ID: 23547050
[TBL] [Abstract][Full Text] [Related]
38. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
Cuenco GM; Ren R
Oncogene; 2004 Jan; 23(2):569-79. PubMed ID: 14724585
[TBL] [Abstract][Full Text] [Related]
39. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.
Gao XN; Lin J; Ning QY; Gao L; Yao YS; Zhou JH; Li YH; Wang LL; Yu L
PLoS One; 2013; 8(2):e55481. PubMed ID: 23390536
[TBL] [Abstract][Full Text] [Related]
40. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide.
Shackelford D; Kenific C; Blusztajn A; Waxman S; Ren R
Cancer Res; 2006 Dec; 66(23):11360-9. PubMed ID: 17145882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
